CRVS

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing precision oncology therapeutics. Headquartered in Burlingame, California, the company focuses on drugs that modulate the tumor microenvironment and immune system to treat cancer. Corvus' lead product candidate, mupadolimab, is an antibody targeting CD73 being evaluated in multiple tumor types including non-small cell lung cancer and head and neck cancer. The company's pipeline also includes ciforadenant, an adenosine A2A receptor antagonist, for various solid tumors.